Global X Genomics & Biotechnology ETF (GNOM) seeks to track the Solactive Genomics Index, which measures the performance of companies developing or utilizing genomic sequencing, gene editing technologies like CRISPR, personalized medicine, and biotechnology innovations. This thematic healthcare ETF provides targeted exposure to the rapidly evolving genetic medicine and biotechnology sectors.
How It Works
GNOM uses a passively managed, modified market-capitalization-weighted approach that tracks companies involved in genomics research, gene therapy development, and biotechnology applications. The fund focuses on pure-play genomics companies and larger firms with significant genomics divisions, including pharmaceutical companies developing gene-based treatments. Holdings are rebalanced semi-annually to maintain alignment with the underlying index, typically containing 40-60 companies ranging from small biotech startups to established pharmaceutical giants with genomics programs.
Key Features
- Pure-play exposure to genomics revolution including CRISPR gene editing, DNA sequencing, and personalized medicine companies
- Captures both established pharmaceutical firms and emerging biotech companies developing breakthrough genetic therapies and diagnostics
- Launched in 2019 to capitalize on genomics sector growth, with 0.68% expense ratio reflecting specialized research requirements
Risks
- This ETF can lose significant value if genomics companies fail clinical trials or face regulatory setbacks, potentially declining 40-60% during biotech bear markets
- Concentrated sector exposure means FDA drug approvals, patent disputes, or changes in healthcare regulations can cause dramatic price swings
- High-growth biotech stocks are extremely volatile and sensitive to interest rate changes, often underperforming during economic uncertainty or rising rates
Who Should Own This
Best suited as a satellite holding (5-10% of portfolio) for aggressive growth investors with 5+ year time horizons and high risk tolerance. Appropriate for investors seeking exposure to the genomics revolution who can withstand extreme volatility. Works well for younger investors in tax-advantaged accounts who want thematic exposure to potentially transformative medical technologies.